USCOM LIMITED — Board/Management Information 2011

Dec 6, 2011

==> picture [54 x 34] intentionally omitted <==

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

Management restructure and operations update

Wednesday 7th of December 2011: Uscom (ASX code: UCM).

Uscom today announced the appointment of Mr Tom Rowe as the new Company Secretary of Uscom Ltd. This appointment completes the restructure of the Company triggered by the failed reelection of two Board members at the AGM on November 22nd.

Tom is a practicing lawyer with qualifications in both applied finance and corporate governance and over 10yrs experience as in house counsel and consultant to both ASX 100 and small cap companies. He specialises in corporate transactions, capital raising, listed company secretarial practice and corporate governance.

Mr Carl Swindle, based in California, has also been appointed as the consultant in charge of development of Uscom Strategic Partnerships. Carl has over 20yrs in the medical device business having been previously employed by Edwards Life Sciences and Research Medical as Director of Business Development. More recently Carl has been active in the bio-device sector specialising in capital raising and strategic partnerships.

As part of the global restructuring Mr Joe Trygar, Senior VP Global Sales and more recently CEO, has left Uscom Ltd. Mr Rob Phillips will assume the vacant CEO role.

As part of the restructuring a review of operations was conducted by the incoming Board to allow development of a new budget in response to the circumstances left by the departing Board. From June 30[th] revenue from sales until Nov 22 was $0.29m, the capitalised value of the Company was $6.25m and cash on hand was approximately $1m.

Executive Director of Uscom, Rob Phillips said, “The current financial situation reflects the prior management strategy, and we are hopeful that the re-motivation of our global distribution partners, particularly in the USA, will result in a boost to revenue, while a renewed focus on cost will further consolidate the Company’s finances. Carl Swindle has been briefed to re-initiate conversations with potential international business partners and investigate opportunities to generate incremental growth. The appointment of Tom Rowe completes the new Board and management appointments and will provide a fresh and objective approach to optimizing the opportunities that are the future of Uscom.”

About Uscom

Uscom Limited is an Australian medical device company which was first listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency Medicine, Intensive Care Units and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of all fluid administration. USCOM has global regulatory approval and the technology is currently marketed in North America, South America, Europe, the Middle East, Australia, New Zealand, China and South East Asia.

Uscom Contacts

Rob Phillips Chief Executive Officer rob@uscom.com.au

Tom Rowe Company Secretary tom.rowe@uscom.com.au